Next Investors logo grey

Rat's Rant: What's hot, what's not and ... more biotech winners

Published 03-OCT-2019 07:52 A.M.


7 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

What's hot

Immuron Limited (ASX:IMC)

Immuron closed up 66% to finish at 17.5c on $3.69 million stock traded. The reason for the rise was a new research agreement with the Naval Medical Research Centre (NMRC), Silver Spring, MD, USA. AU$5.5 (US$3.7) million funding was approved by the U.S. Department of Defense to develop and clinically evaluate a new oral therapeutic targeting Campylobacter and ETEC.

Sounds like they might have a cure for the sh*ts.... so that would be handy for some people at my work!

Immuron is focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron has a novel and safe technology platform with one commercial asset Travelan® generating revenue. Immuron’s lead clinical candidate, IMM-124E, is presently being developed as a drug to prevent Travelers’ Diarrhea (gotta hate that).

Immuron’s second clinical-stage asset, IMM-529, targets Clostridium difficile Infections (CDI), and is presently in a clinical trial in CDI patients.

Details on yesterday's news are listed below for yet another bio tech winner.

New U.S. Department of Defense Research Collaboration with Immuron to Develop and Clinically evaluate a New Therapeutic against Campylobacter

Key Highlights:

  • AU $5.5 (USD $3.7) million funding approved by the U.S. Department of Defense to developand clinically evaluate a new oral therapeutic targeting Campylobacter and ETEC
  • Naval Medical Research Centre will fund the manufacture and therapeutic evaluation of the therapeutic to protect against acute infectious diarrhea
  • Two human clinical trials to be conducted with new therapeutic under terms of grant

Landmark White Limited (ASX:LMW)

Landmark White closed up 55% to finish at 17c on $240,000 stock traded on the back of the announcement that they caught one of the crooks that had cyber hacked them and caused major distributions to their business.

It wasn't that long ago that the boys and girls at Enrizen Capital offered me stock at 8c, which was part of the re cap that had to be done because of these cyber criminals.

LMW was founded in 1982 and listed on the Australian Stock Exchange in 2003. It has a long and proud heritage of providing independent professional property services to people and companies across Australia.

LMW has over 300 property professionals across 40 plus locations Australia wide and offers a wide range of services which includes commercial and residential valuations, research, and property advice with a focus in providing unrivalled property services that minimise the risks to our clients.

So well done to Frank, Trent and the team at Enrizen and good luck to the Landmark shareholders and management in the future.

I just wish I took some 8c stock.

Some details from the company's announcement are listed below:

Arrest Made In Relation to Cyber Incident

LMW is pleased to advise that NSW Police Force Cybercrime Squad has made an arrest in connection with the cyber incidents that have affected LMW throughout 2019.

We have been working closely with the NSW Police Force Cybercrime Squad since the breach to identify the person behind this incident, and we are grateful that the person arrested today was not one of our employees.

Investigations have revealed that the breach was carried out by someone with trusted inside access and we believe we were deliberately targeted by someone with an intent to damage our business and reputation. We are working with the Cybercrime Squad to understand the motives for these actions.

We have made considerable investment and system enhancements this year. We are fully compliant with the International Standard ISO27001 – Information Security Management, and will soon be externally certified to this Standard.

We are pleased that a number of financial institutions have reinstated LMW to their panels of valuation providers, and we continue to work with all our partners to provide them with the information they need to be satisfied our operations are secure and/or best practice.

We have been a trusted member of the industry for nearly 40 years and we look forward to putting this incident behind us and getting back to work with all our clients and partners across Australia.

Next Investors Image

Mayne Pharmaceuticals Limited (ASX:MYX)

Mayne closed up 19% to finish at 63c on $33.1 million stock traded. It's another biotech winner - albeit no a penny dreadful - but boy isn't this biotech space hot at the moment.

The reason for the rise is they have signed a 20-year exclusive supply and license agreement with Mithra Pharmaceuticals, SA to commercialise a novel oral contraceptive comprising Estetrol (E4), and drospirenone, (E4/DRSP) in the United States.

Mayne Pharma is focused on applying its drug delivery expertise to commercialise branded and generic pharmaceuticals, providing patients with access to better and more affordable medicines. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide.

Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that have been marketed around the world.

Mayne Pharma has two product development and manufacturing facilities based in Salisbury, Australia and Greenville, USA with expertise in the formulation of complex oral dose forms including potent compounds, controlled substances, modified-release products and inherently unstable compounds.

Some details on today's news are listed below:


  • Mayne Pharma Group Limited (Mayne Pharma or Company) (ASX:MYX) has signed a 20-year exclusive supply and license agreement with Mithra Pharmaceuticals, SA (Mithra) to commercialise a novel oral contraceptive comprising Estetrol (E4), and drospirenone, (E4/DRSP) in the United States
  • Phase 3 clinical studies which enrolled more than 3,700 women have been completed. Approval and launch expected first half of calendar 2021
  • US contraceptive market is valued at US$5.4 billion with 10 million American women using short-acting combined hormonal contraceptives
  • Expected to be EBITDA positive in its first full financial year following approval
  • Peak net sales potential to exceed US$200 million per annum
  • Significantly leverages Mayne Pharma’s existing leadership position in the US branded generic oral contraceptive market and enhances the potential of pipeline assets such as generic NUVARING®
  • Consideration paid will include a mix of upfront equity and cash along with further equity and cash at FDA approval, together with sales-based milestone cash payments.

Cohiba Minerals Limited (ASX:CHK)

Cohiba Minerals closed up 14% to finish at 1.7c on $400,000 stock traded. There was no news in the market and hasn't been for a while, but these blokes have their hands in plenty of pies, so don't be surprised to see one of those pies start to warm up, whether it be IOCG, Gypsum, Copper or maybe even the Gold stuff.

I reckon something's cooking ...

Cohiba Minerals Limited is listed on the Australian Securities Exchange (ASX) with the primary focus of investing in the resource sector through direct tenement acquisition, joint ventures, farm in arrangements and new project generation.

Next Investors Image

What's not

Actinogen Medical Limited (ASX:ACW)

Actinogen closed down 26% to finish at 3.8c on $21.8 million stock traded. The stock was up 400% plus yesterday, so something had to give.

The reason they were up was due to the results from the XanaHES (Xanamem in Healthy Elderly Subjects) trial. The results demonstrate a significant improvement in cognition in trial participants dosed with Xanamem 20mg daily for 12 weeks, compared to placebo.

This is the first time Xanamem has shown such a clear, statistically significant cognitive improvement in humans.

They actually opened yesterday at 5.5c, traded as high as 6.6c, hit a low of 3.4c and finished the day @ 3.8c.

What a wild day's trading, kinda wish I was part of it.

Well done to Bill and his team and I will be in touch big fella.

Finfeed covered the announcement yesterday.

Go hard.

The Rat.

Note: The idea of this report is to be informative and hopefully point out some stocks that you wouldn't ordinarily have seen during the day. This report IS NOT personal advice. Finfeed DOES NOT PROVIDE personal advice. All advice included in The Rat’s Rant is General Advice. Please refer to the General Advice Warning below.

The views expressed in this report are The Rat's and may not necessarily reflect the same views as Finfeed. It is very important to refer to the ASX website for information on any companies / stocks that are contained in this report and as always please consult your financial adviser before acting.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.